Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse-Deterrent Oxycodone Product ELI-201
December 03, 2014 09:55 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence (BE) study for...
Elite Pharmaceuticals Initiates Pivotal Bioequivalence Study for ELI-201
July 15, 2014 10:31 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 15, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today the first dosing of a pivotal bioequivalence study in healthy...
Elite Pharmaceuticals Reports Successful Pivotal Bioequivalence Study for Abuse Deterrent Product ELI-200
March 05, 2014 07:30 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., March 5, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) announced today successful results from a pivotal bioequivalence study initiated...
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
February 18, 2014 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...